Skip to main content
. 2020 Apr 14;323(14):1378–1387. doi: 10.1001/jama.2020.3138

Figure 2. Cumulative Incidence of Cytomegalovirus (CMV) Disease With Death as a Competing Risk.

Figure 2.

Cumulative incidence curves of CMV disease show that the antiviral prophylaxis group had more postprophylaxis (delayed-onset) CMV disease than the preemptive therapy group (P = .048); the curves begin to separate about 4 to 6 weeks after the study drug administration period. Death prior to CMV disease was considered a competing risk. The number at risk is patients alive without CMV disease. The median follow-up for patients was 1152 days (interquartile range, 541 to 1537 days) in the preemptive therapy group and 1020 days (interquartile range, 588 to 1450 days) in the antiviral prophylaxis group.